Cochlear Implant
DeviceTICI G2 Clinical Investigation System
NCT Number: NCT07139327
This clinical study examines the performance of an investigational totally implantable cochlear implant (TICI) system. The system includes an implantable microphone under the skin to detect speech and sound from the environment allowing the option to hear without the need of an external sound processor. This implant will be tested in adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve (the nerve that carries sound signals from the ear to the brain). The study participants will undergo a series of tests that include testing their implant and their hearing. They will also complete questionnaires to see how they rate their hearing and overall general health.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Interventional
Not applicable
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
TICI G2 Clinical Investigation System
Time frame: Preimplantation to 6 months post-activation
Percent correct word score from preimplantation to post-activation
Time frame: Implantation to 6 and 12 months post-activation
Frequency and severity of device and procedure-related adverse events, including device deficiencies
Time frame: Preimplantation to 12 months post-activation
Percent correct scores for word tests in quiet and speech reception threshold scores for sentence tests in noise
Time frame: Preimplantation to 12 months post-activation
Speech, Spatial, and Qualities of Hearing Scale Global score (SSQ-12). Scores range from 0 to 10, where higher scores indicate greater ability (less hearing disability).
Time frame: Preimplantation to 12-months post-activation
Cochlear implant hearing related quality of life score (CIQOL-35). Scored for six health domains (communication, emotional, entertainment, environment, listening effort, and social) each scaled from 0 to 100, where a higher score indicates better health.
Time frame: Preimplantation to 12 months post-activation
Health Utilities Index (HUI 2/3) Global score. Scores range from -0.36 to 1.00, where a negative score represents a state "worse than dead" and a top score of 1.00 is "perfect health"
Time frame: Preimplantation to 12 months post-activation
Living with Cochlear Implants Questionnaire (LivCI) evaluates the impact of a hearing device on four domains, Participation (range 0 to 12), Psychosocial & Wellbeing (range 0 to 21), Stigma (range 0 to 15) and Management & Aesthetics (range 0 to 18), where a higher domain score indicates positive patient report.
Time frame: 6 to 12 months post-activation
Device satisfaction rating score. Scores range from 1 to 5, where a higher score indicates greater patient satisfaction with the TICI system.
Time frame: 8 to 10 months post-activation
SF-36 is scored for eight health domains, each scaled from 0 to 100, where a higher score indicates better health.
Time frame: Initial activation to 12 months post-activation
Hours of TICI System usage
Cochlear
Industry
A Pre-market, Prospective, Interventional, Multicenter, Pivotal Study to Evaluate Efficacy and Safety of a Totally Implantable Cochlear Implant System in an Adult Population With Sensorineural Hearing Loss
Acronym: ENTERPRISE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06424262
Ear Diseases, Hearing Disorders
Sydney, New South Wales, Australia
View Trial DetailsNCT07287124
Ear Diseases, Hearing Disorders
Englewood, Colorado, United States
View Trial DetailsNCT07421349
Children, Ear Diseases
Istanbul, Sakarya, Turkey (Türkiye)
View Trial DetailsNCT07584837
Ear Diseases, Hearing Disorders
Los Angeles, California, United States
View Trial Details